Nilotinib (AMN-107, Tasigna) is a Bcr-Abl inhibitor with IC50 less than 30 nM. Nilotinib has entered in a phase IV clinical trial in the treatment of philadelphia chromosome positive and chronic myelogenous leukemia in chronic phase. Nilotinib is a selec
CAS Number:
[641571-10-0]
Application Notes:
BNL
* VAT and and shipping costs not included. Errors and price changes excepted